Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review

Survey of Ophthalmology

Volumn 60, Issue 6, 2015, Pages 524-535

  Kim, Megan ^a   Lee, Chelsea ^a   Payne, Rachael ^a   Yue, Beatrice Y J T ^a   Chang, Jin Hong ^a   Ying, Hongyu ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Angiogenesis; Anti metabolites; Anti VEGF therapy; Bevacizumab; Glaucoma; Glaucoma filtration surgery; Neovascular glaucoma; Ranibizumab

Indexed keywords

BEVACIZUMAB; CHEMOKINE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA1; FIBRONECTIN; FLUOROURACIL; MATRIX METALLOPROTEINASE; MITOMYCIN; RANIBIZUMAB; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTIMETABOLITE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; AQUEOUS HUMOR OUTFLOW; BLEB INFECTION; BLEB LEAKAGE; BLINDNESS; CELL PROLIFERATION; CYSTIC AVASCULAR BLEB; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; ENZYME INHIBITION; FIBROBLAST; HUMAN; HYPOTONY MACULOPATHY; IN VITRO STUDY; INTRAOCULAR PRESSURE; INTRAOPERATIVE PERIOD; LASER COAGULATION; MOLECULARLY TARGETED THERAPY; NEOVASCULAR GLAUCOMA; NONHUMAN; OPEN ANGLE GLAUCOMA; OPEN STUDY; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; PILOT STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ISCHEMIA; REVIEW; TRABECULECTOMY; TREATMENT OUTCOME; UPREGULATION; VISUAL ACUITY; WOUND HEALING; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; FILTERING OPERATION; GLAUCOMA, NEOVASCULAR; IRIS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIMETABOLITES; BEVACIZUMAB; COMBINED MODALITY THERAPY; FILTERING SURGERY; GLAUCOMA, NEOVASCULAR; HUMANS; IRIS; LASER COAGULATION; NEOVASCULARIZATION, PATHOLOGIC; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949625229     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2015.04.003     Document Type: Review

References (129)

1. Adair TH, Montani JP. Angiogenesis. San Rafael (CA), Morgan & Claypool Life Sciences; 2010.
2. Al-Halafi AM. Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside. Oman J Ophthalmol. 2014;7:112-5.
3. Allingham RR, Shields MB. Shields' Textbook of Glaucoma. Philadelphia, Ovid Technologies Inc; 2011, pp 294-308.
4. Anchala AR, Pasquale LR. Neovascular glaucoma: a historical perspective on modulating angiogenesis. Semin Ophthalmol. 2009;24:106-12.
5. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
6. Bao P, Kodra A, Tomic-Canic M, et al. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009;153:347-58.
7. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-10.
8. Bermudez DM, Xu J, Herdrich BJ, et al. Inhibition of stromal cell-derived factor-1a further impairs diabetic wound healing. J Vasc Surg. 2011;53:774-84.
9. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:271-9.
10. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-28.
11. Brouzas D, Charakidas A, Moschos M, et al. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol. 2009;3:685-8.
12. Bry M, Kivela R, Holopainen T, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010;122:1725-33.
13. Cai J, Jiang WG, Ahmed A, Boulton M. Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc Res. 2006;71:20-31.
14. Cantor LB, Mantravadi A, WuDunn D, et al. Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb Appearance Grading Scale. J Glaucoma. 2003;12:266-71.
15. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-60.
16. Casson RJ, Chidlow G, Wood JP, et al. Definition of glaucoma: clinical and experimental concepts. Clin Experiment Ophthalmol. 2012;40:341-9.
17. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132:1350-4.
18. Chang JH, Garg NK, Lunde E, et al. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415-29.
19. Chen S, Feng J, Ma L, et al. RNA interference technology for anti-VEGF treatment. Expert Opin Drug Deliv. 2014;11:1471-80.
20. Chua BE, Nguyen DQ, Qin Q, et al. Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: a pilot study. Clin Experiment Ophthalmol. 2012;40:773-9.
21. Cohen LP, Pasquale LR. Clinical characteristics and current treatment of glaucoma. Cold Spring Harb Perspect Med. 2014;4:a017236.
22. Cordeiro MF, Bhattacharya SS, Schultz GS, et al. TGF-beta1,-beta2, and-beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000;41:756-63.
23. Coso S, Zeng Y, Opeskin K, et al. Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS One. 2012;7:e39558.
24. Costagliola C, Cipollone U, Rinaldi M, et al. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol. 2008;66:667-73.
25. Crawford TN, Alfaro DV 3rd, Kerrison JB, et al. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009;5:8-13.
26. Dandona L, Dandona R. What is the global burden of visual impairment? BMC Med. 2006;4:6.
27. Delgado MF, Dickens CJ, Iwach AG, et al. Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology. 2003;110:895-9.
28. Deva NC, Insull E, Gamble G, et al. Risk factors for first presentation of glaucoma with significant visual field loss. Clin Experiment Ophthalmol. 2008;36:217-21.
29. Duch S, Buchacra O, Milla E, et al. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009;18:140-3.
30. Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28:696-702.
31. Ellenberg D, Azar DT, Hallak JA, et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. 2010;29:208-48.
32. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14:4500-10.
33. Feng Y, Wang W, Hu J, et al. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in nonsmall cell lung cancer. Anat Rec (Hoboken). 2010;293:802-12.
34. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-8.
35. Fong AW, Lee GA, O'Rourke P, et al. Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab. Clin Experiment Ophthalmol. 2011;39:318-23.
36. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007;27:816-24.
37. Fruttiger M. Development of the retinal vasculature. Angiogenesis. 2007;10:77-88.
38. Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164:1935-47.
39. Georgoulas S, Dahlmann-Noor A, Brocchini S, et al. Modulation of wound healing during and after glaucoma surgery. Prog Brain Res. 2008;173:237-54.
40. Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52-9.
41. Grewal DS, Jain R, Kumar H, et al. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology. 2008;115:2141-5.e2142.
42. Group CATTS, Grehn F, Hollo G, et al. Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152. Ophthalmology. 2007;114:1831-8.
43. Group CATTS, Khaw P, Grehn F, et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007;114:1822-30.
44. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26:470-85.
45. Hazin R, Hendrick AM, Kahook MY. Primary open-angle glaucoma: diagnostic approaches and management. J Natl Med Assoc. 2009;101:46-50.
46. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48.
47. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-80.
48. Hogewind BF, Pijl B, Hoyng CB, et al. Purified triamcinolone acetonide as antifibrotic adjunct in glaucoma filtering surgery. Graefes Arch Clin Exp Ophthalmol. 2013;251:1213-8.
49. Honjo M, Tanihara H, Kameda T, et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549-57.
50. How A, Chua JL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2010;51:928-32.
51. Hu DN, Ritch R, Liebmann J, et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-10.
52. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52.
53. Jampel HD, Solus JF, Tracey PA, et al. Outcomes and blebrelated complications of trabeculectomy. Ophthalmology. 2012;119:712-22.
54. Jurkowska-Dudzinska J, Kosior-Jarecka E, Zarnowski T. Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Experiment Ophthalmol. 2012;40:e135-42.
55. Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010;150:399-403. e391.
56. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5:74-80.
57. Khasraw M, Pavlakis N, McCowatt S, et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010;21:1302-7.
58. Khaw PT, Chiang M, Shah P, et al. Enhanced trabeculectomy: the Moorfields Safer Surgery System. Dev Ophthalmol. 2012;50:1-28.
59. Kim YG, Hong S, Lee CS, et al. Level of vascular endothelial growth factor in aqueous humor and surgical results of Ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma. 2009;18:443-7.
60. Kirwan JF, Lockwood AJ, Shah P, et al. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology. 2013;120:2532-9.
61. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25:438-43.
62. Kiuchi Y, Nakae K, Saito Y, et al. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:1627-32.
63. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2:a006502.
64. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol. 2011;129:145-50.
65. Kovacic Z, Ivanisevic M, Rogosic V, et al. [Cyclocryocoagulation in treatment of neovascular glaucoma]. Lijec Vjesn. 2004;126:240-2.
66. Kuzmin A, Lipatov D, Chistyakov T, et al. Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma. Ophthalmol Ther. 2013;2:41-51.
67. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-46.
68. Li WW, Talcott KE, Zhai AW, et al. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care. 2005;18:491-500, quiz 501-492.
69. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217-25.
70. Lim TH, Bae SH, Cho YJ, et al. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol. 2009;23:188-92.
71. Liu ZY, Qiu HO, Yuan XJ, et al. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin. Int J Oncol. 2012;41:1762-72.
72. Lopilly Park HY, Kim JH, Ahn MD, et al. Level of vascular endothelial growth factor in tenon tissue and results of glaucoma surgery. Arch Ophthalmol. 2012;130:685-9.
73. Lorenzon E, Colladel R, Andreuzzi E, et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene. 2012;31:3136-47.
74. Luke J, Nassar K, Luke M, et al. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucomadresults from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013;251:2403-13.
75. McBride JD, Jenkins AJ, Liu X, et al. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol. 2014;134:1725-34.
76. Md Noh SM, Sheikh Abdul Kadir SH, Bannur ZM, et al. Effects of ranibizumab on the extracellular matrix production by human Tenon's fibroblast. Exp Eye Res. 2014;127:236-42.
77. Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-401.
78. Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009;50:3233-7.
79. Mosaed S, Minckler DS. Aqueous shunts in the treatment of glaucoma. Expert Rev Med Devices. 2010;7:661-6.
80. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251-75.
81. Nauta A, Seidel C, Deveza L, et al. Adipose-derived stromal cells overexpressing vascular endothelial growth factor accelerate mouse excisional wound healing. Mol Ther. 2013;21:445-55.
82. Nilforushan N, Yadgari M, Kish SK, et al. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012;153:352-7.e351.
83. O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2010;51:6524-32.
84. Ozgonul C,Mumcuoglu T, Gunal A. The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res. 2014;39:451-9.
85. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171-85.
86. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye (Lond). 2008;22:1330-6.
87. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocytemediated mechanism. Circ Res. 2003;92:378-85.
88. Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol. 2014;9:142-60.
89. Razeghinejad MR, Fudemberg SJ, Spaeth GL. The changing conceptual basis of trabeculectomy: a review of past and current surgical techniques. Surv Ophthalmol. 2012;57:1-25.
90. Rehman SU, Amoaku WM, Doran RM, et al. Randomized controlled clinical trial of beta irradiation as an adjunct to trabeculectomy in open-angle glaucoma. Ophthalmology. 2002;109:302-6.
91. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853-65.
92. Rossiter H, Barresi C, Pammer J, et al. Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res. 2004;64:3508-16.
93. Saeedi OJ, Jefferys JL, Solus JF, et al. Risk factors for adverse consequences of low intraocular pressure after trabeculectomy. J Glaucoma. 2014;23:e60-8.
94. Saito Y, Higashide T, Takeda H, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol. 2010;88:96-102.
95. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
96. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15:119-26.
97. Seet LF, Finger SN, Chu SW, et al. Novel insight into the inflammatory and cellular responses following experimental glaucoma surgery: a roadmap for inhibiting fibrosis. Curr Mol Med. 2013;13:911-28.
98. Seibold LK, Sherwood MB, Kahook MY. Wound modulation after filtration surgery. Surv Ophthalmol. 2012;57:530-50.
99. Sengupta S, Venkatesh R, Ravindran RD. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma. 2012;21:450-9.
100. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153:13-9.
101. Shibuya M. VEGF-VEGFR signals in health and disease. Biomol Ther (Seoul). 2014;22:1-9.
102. Simha A, Braganza A, Abraham L, et al. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013;(10):CD007920.
103. Sivak-Callcott JA, O'Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-76, quiz1777, 1800.
104. Spaeth GL, Mutlukan E. The use of antimetabolites with trabeculectomy: a critical appraisal. J Glaucoma. 2001;10:145-51.
105. Suh W, Kee C. The effect of bevacizumab on the outcome of trabeculectomy with 5-fluorouracil. J Ocul Pharmacol Ther. 2013;29:646-51.
106. Szekanecz Z, Besenyei T, Szentpetery A, et al. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 2010;22:299-306.
107. Takeuchi K, Nakazawa M, Ebina Y. Effects of trehalose on VEGF-stimulated angiogenesis and myofibroblast proliferation: implications for glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2011;52:6987-93.
108. Takeuchi K, Nakazawa M, Ebina Y, et al. Inhibitory effects of trehalose on fibroblast proliferation and implications for ocular surgery. Exp Eye Res. 2010;91:567-77.
109. Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol. 2008;28:322-8.
110. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121:2081-90.
111. Van Bergen T, Vandewalle E, Van de Veire S, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res. 2011;93:689-99.
112. Vandewalle E, Abegao Pinto L, Van Bergen T, et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014;98:73-8.
113. Vasudev D, Blair MP, Galasso J, et al. Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther. 2009;25:453-8.
114. Vempati P, Popel AS, Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014;25:1-19.
115. Waisbourd M, Shemesh G, Kurtz S, et al. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014;93:108-12.
116. Weinheimer-Haus EM, Judex S, Ennis WJ, et al. Lowintensity vibration improves angiogenesis and wound healing in diabetic mice. PLoS One. 2014;9:e91355.
117. Weiss DI, Shaffer RN, Nehrenberg TR. Neovascular gluacoma complicating carotid-cavernous fistula. Arch Ophthalmol. 1963;69:304-7.
118. Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-90.
119. Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;(4):CD002897.
120. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
121. Wu Y, Lucia K, Lange M, et al. Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas. J Neurooncol. 2014;119:263-73.
122. Yang F, Jin C, Jiang YJ, et al. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert Rev Anticancer Ther. 2011;11:541-9.
123. Yang H, Shin S, Ahn J, et al. Local injection of pulp cells enhances wound healing during the initial proliferative phase through the stimulation of host angiogenesis. J Endod. 2013;39:788-94.
124. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69-76.
125. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18:632-7.
126. Ye W, Liu R, Pan C, et al. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol Ther. 2014;22:1221-9.
127. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A. 2009;106:6152-7.
128. Zhang W, Ran S, Sambade M, et al. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis. 2002;5:35-44.
129. Zhou M, Chen S, Wang W, et al. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2013;54:3874-9.